Securities code: Ningbo Menovo Pharmaceutical Co.Ltd(603538) securities abbreviation: Ningbo Menovo Pharmaceutical Co.Ltd(603538) Announcement No.: 2022033 bond Code: 113618 bond abbreviation: Meinuo convertible bond
Ningbo Menovo Pharmaceutical Co.Ltd(603538)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
1、 Details of abnormal fluctuations in stock trading
The closing price of the company’s shares fell by more than 20% in two consecutive trading days on March 31 and April 1, 2022, which belongs to the abnormal fluctuation of stock trading stipulated in the trading rules of Shanghai Stock Exchange.
2、 Relevant information concerned and verified by the company
In view of the abnormal fluctuation of the company’s stock trading, the company has conducted self-examination on relevant matters and consulted the controlling shareholder and actual controller of the company in writing for verification. The relevant information is explained as follows:
(I) production and operation
The company is a pharmaceutical manufacturing enterprise specializing in the R & D, production and sales of characteristic APIs (including intermediates) and finished drugs.
The company disclosed the third quarter report of 2021 on October 28, 2021. From January to September, 2021, the company realized an operating revenue of 9187033 million yuan, a year-on-year decrease of 3.18%; The net profit attributable to the shareholders of the listed company: 1353914 million yuan, a year-on-year decrease of 4.04%; Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses: 1143872 million yuan, a year-on-year decrease of 10.62%.
According to the company’s preliminary accounting, the company realized an operating revenue of about 253.37 million yuan from January to February 2022, with a year-on-year increase of 54%; The net profit was about 60.55 million yuan, a year-on-year increase of 416%. The above main operating data have not been audited and are only the accounting results of the company’s financial department. They are only used as phased financial data for investors’ reference and cannot be used to calculate the company’s future stage and annual performance.
According to the company’s self inspection, the company’s current production and operation are normal, the internal and external business environment has not changed significantly, the main business has not changed significantly, and there are no other major information that should be disclosed but not disclosed.
(II) project filing
On March 15, 2022, the company disclosed the relevant matters passed the filing of the “new project with an annual output of 60 tons of anti covid-19 drug nimatovir API and its key intermediates”. The main risks are as follows:
1. The company does not directly supply relevant intermediates to the patent owner and has no direct commercial cooperation with the patent owner.
2. At present, the API of nimatovir studied by the company has not obtained relevant authorization and is only used for laboratory research and development. Due to the patent protection of relevant APIs, the company may have legal risks caused by patent infringement, such as the inability to continue to develop and declare APIs, the inability to form regulatory market sales, and the retroactive infringement liability of regulatory market sales.
3. The company’s nimatovir (API) is currently in the laboratory research and development stage. In the follow-up, it still needs to carry out pilot scale production process verification, further research, registration and filing of quality standards and stability, and arrange production certification according to the requirements of the target market. There may be risks such as process research and development failure, registration and declaration failure, and there is uncertainty whether it can realize commercial production.
4. Intermediates SM1, SM2 and T13 are pharmaceutical and chemical products without compound patents, with full market competition and are not produced exclusively by the company. They may face risks such as intensified market competition and changes in market demand in the future. At present, there are many similar types of APIs and intermediates on the market, the market competition is fierce, and there is uncertainty about whether the market demand will change in the future.
5. There is a risk that the price of raw materials and the supply of raw materials for the project will rise sharply.
Detailed risk tips have been listed item by item in Ningbo Menovo Pharmaceutical Co.Ltd(603538) announcement on holding subsidiary’s obtaining project filing. For details, please refer to the above announcement, Announcement No.: 2022020. (III) major events
After the company’s self-examination and written consultation and verification with the controlling shareholders and actual controllers: as of the disclosure date of this announcement, the company, the controlling shareholders and actual controllers have no major information that should be disclosed but not disclosed, including but not limited to the major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase, equity incentive, bankruptcy reorganization Major business cooperation, introduction of strategic investors and other major issues.
(IV) media reports and market rumors
1. Recently, some investors have paid attention to “whether the company has laid out auxiliary reproduction, and elderly care business industries”. After verification by the company, the relevant business conditions are explained as follows: the company’s main business does not involve auxiliary reproduction and elderly care industries. Ningbo Ningbo Menovo Pharmaceutical Co.Ltd(603538) Ruihe equity investment partnership (hereinafter referred to as “Ruihe fund”) with 32% of the company’s shares invested 7.5% of the equity of Jiangsu Meike Medical Technology Co., Ltd. (hereinafter referred to as “Meike medical”), with an investment amount of only 30 million. Ruihe fund and Meike medical are not within the scope of the company’s consolidated statements, with a small proportion of shares and little impact. Merck medical’s business scope involves gynecological testing and assisted reproduction, but the two businesses account for a low proportion and have little impact on the company’s performance.
2. Recently, the company has paid attention to the research minutes of the company on the Internet, and the risk tips are as follows:
(1) At present, the company has not carried out commercial cooperation with Japanese covid-19 specific drug manufacturer yanyeyi Pharmaceutical Co., Ltd. and domestic covid-19 specific drug manufacturers targeting RdRp, and the relevant intermediate products have not been mass produced. It is uncertain whether the subsequent commercial cooperation can be reached.
(2) At present, the existing capacity of SM1 and SM2 of the company is 10 tons per month. The actual sales and production depend on the downstream demand and raw material supply, which is uncertain. The relevant production expansion projects are still in the preparatory stage, and the construction cycle is long. There is still uncertainty whether the construction can be completed on schedule and reach production. At the same time, affected by the changes of covid-19 epidemic outside China and the gradual release of relevant drug production capacity, the product price and gross profit margin fluctuate, and the contribution to the company’s revenue fluctuates and is uncertain.
(V) other stock price sensitive information
It is verified that the company’s directors, supervisors, senior managers, controlling shareholders, actual controllers and their persons acting in concert and other important shareholders did not buy or sell the company’s shares during the abnormal fluctuation of this stock trading. The company has not found any other major events that may have a great impact on the company’s share price.
3、 Relevant risk tips
(I) the deviation of the closing price of the company’s shares from the value accumulated in two consecutive trading days on March 31, 2022 and April 1, 2022 exceeds 20%.
Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
(II) the company solemnly reminds investors that the information disclosure media designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN) According to China Securities News, Shanghai Securities News and securities times, the relevant information of the company shall be subject to the announcement published by the company in the above designated media. Please invest rationally and pay attention to investment risks.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that up to now, the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules of Shanghai Stock Exchange or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules of Shanghai Stock Exchange For the information that may have a great impact on the trading price of the company’s shares and their derivatives, the information disclosed by the company in the early stage does not need to be corrected or supplemented.
The information disclosure media designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN.) According to China Securities News, Shanghai Securities News and securities times, the relevant information of the company shall be subject to the announcement published by the company in the above designated media. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Ningbo Menovo Pharmaceutical Co.Ltd(603538) board of directors April 2, 2022
